Clinical trial details

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Identifier

NVL-655-01

Sponsor

NUVALENT, INC.

Principal Investigator

ENRIQUETA FELIP FONT

Service

Oncology

Study details

Tumor type: ALL SOLID TUMORS
Stage: Advanced
Main Investigational Agent : Targeted therapy
Phase: I
Randomization: Non-randomized

Molecular details

Biomarker: ALK alt
Biomarker criteria: Mandatory
Prescreening: Local
Additional study population requirements: Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented ALK rearrangement or activating ALK mutation.

Drug details

Arm A: NVL-655

Links

Clinical Trials GOV (NCT identifier): NCT05384626
EU Clinical Trials Register (eudraCT Identifier): 2022-000122-21